Understanding the neural substrates underlying pharmacological action on different neurotransmitter systems is a key facet of neuroscience research and critical in the development of new treatments in psychiatry (Matthews et al., 2006) . The initial efforts to incorporate combined neuroimaging techniques, including magnetoencephalography (MEG) and proton magnetic resonance spectroscopy (MRS), into the study of brain functioning indicate a high potential of such an approach in advancing the research on pharmacotherapy of psychiatric disorders, including depression and anxiety disorders. For example, the possible sensitivity of MEG measures to γ-aminobutyric acid (GABA) mediated inhibition suggests that the measurement of induced gamma-oscillation frequency in an individual may be useful within the context of pharmacological manipulations (Muthukumaraswamy et al., 2009 ). In the current study, we applied for the first time both MEG and MRS measurements in healthy volunteers medicated with the highly selective serotonin re-uptake inhibitor (SSRI) antidepressant escitalopram.
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Fifteen right handed, healthy volunteers (seven females and eight males) with a mean age of 23.4 (range 19-40) years received escitalopram (10 mg/day) for a total of 7-10 days in open-label, not placebo controlled manner. MRS scanning following MEG measurements was performed twice: once before and once after medication in all participants on a 3T Siemens TIM Trio scanner (Erlangen, Germany) with a body coil transmitter and a 32-channel receive head array. Data were acquired from a 20 mm × 25 mm × 20 mm voxel located in the occipital cortex (OCC). The voxel was positioned manually by reference to an axial T1-weighted gradient echo image. SPECIAL data with water suppression were acquired (TE 8.5 s, 3200 ms, 16-step phase cycle, 128 averages for the occipital voxel). Following spectral processing, SPECIAL data were analysed with LCModel version 6.2-2B using a basis set that consisted of 21 simulated metabolite basis spectra. Basis spectra were generated using an in-house, MATLAB (Natick, MA, USA) based implementation of the density matrix formalism to simulate the effect of the SPECIAL pulse sequence on each of the 21 metabolite spin systems studied. For more information about the accuracy and reliability of SPECIAL in conjunction with the LCModel in the measurement of GABA concentrations see Near et al. (2013) . MEG data were acquired from eight of the 15 mentioned above subjects using an Elekta Neuromag 306-channel system (Elekta, Stockholm, Sweden; 204 planar gradiometers, 102 magnetometers). MEG data were first visually inspected to remove channels severely affected by noise, and then de-noised and corrected for head movements using Elekta's Maxfilter Signal Space Separation algorithm (Taulu et al., 2004) , making use of the spatiotemporal filter algorithm to detect noise components. The anatomical images from MRI were used to create single-shell MEG forward models fitted to each subject's anatomy (Nolte, 2003) . Using SPM's spm_eeg_inv_ mesh a transformation was computed for each subject, mapping a set of canonical meshes for cortical surface, skull and scalp to the subject's anatomy. The individual MEG forward models were derived from these transformations using Fieldtrip's forward toolbox (Oostenveld et al., 2011) . Data were band-pass filtered between 30 and 120Hz, and then transformed from sensor-space into source-space using a linearly constrained minimum variance beamformer (Woolrich et al., 2011) . Each subject's source-space map for left and right gratings was then visually inspected (using FMRIB Software Library's viewer) to locate the voxels with the visual cortex with the strongest gamma activation to the stimulus. The gamma peak frequency was found by averaging the data over the time interval from 300ms to 1000ms relative to stimulus onset and compared with a baseline period from -1000ms to -200ms relative to the stimulus. The peak gamma frequency was found by computing the ratio between power in the stimulus period and baseline period for each frequency bin. The frequency bin with the largest relative change between baseline and stimulus period was taken as the gamma peak frequency for that subject. The effects of escitalopram treatment on MRS and MEG measurements were compared by paired t tests in SPPS v.20 (SPSS Inc., Chicago, IL, USA).
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We found no effect of escitalopram medication on any metabolite concentrations in OCC, including GABA (pre 0.22 ± 0.05 and post 0.21 ± 0.04; p=0.89), glutamate (pre 1.12 ± 0.12 and post 1.11 ± 0.13; p=0.80), glutamine (pre 0.22 ± 0.05 and post 0.24 ± 0.06; p=0.08), glutathione (pre 0.19 ± 0.02 and post 0.20 ± 0.02; p=0.65) and N-acetyl-aspartate (pre 1.57 ± 0.10 and post 1.59 ± 0.10; p=0.56); however, the level of N-acetylaspartylglutamate significantly reduced after antidepressant treatment (pre 0.13 ± 0.03 and post 0.11 ± 0.02; p=0.04). In addition, short-term escitalopram treatment did not significantly influence gamma peak frequency (pre 47.6 ± 15.7 and post 43.8 ± 14.3; t=0.52, p=0.31) . However three of eight subjects showed decrease and one showed increase in gamma-response following the medication (Figure 1) .
The previous MRS studies of antidepressant treatment on brain metabolites have produced conflicting results. For example, a significant increase in OCC GABA concentrations was seen after SSRI treatment in patients with depression (Sanacora et al., 2002) and after single intravenous administration of citalopram (10mg) in healthy volunteers (Bhagwagar et al., 2004) . In addition, one week of citalopram administration was associated with an increase in the combined measure of glutamate and glutamine levels in a posterior cortical region, but not in the frontal cortex in healthy volunteers (Taylor et al., 2008 (Taylor et al., , 2010 . However, the same group found short-term treatment with escitalopram (10 mg) also elevated N-acetyl-aspartate concentration in medial frontal cortex in depressed patients (Taylor et al., 2012) . Nevertheless, their most recent study using the same MRS technique and method failed to show any changes in OCC concentrations of GABA, glutamate or glutathione in depressed patients following six-week escitalopram treatment (Godlewska et al., 2015) .
Our MEG findings should be considered as preliminary only and thus interpreted with caution due to the small sample and no control group included in the study design. Also, although no significant effect of short-term treatment with escitalopram on gamma-oscillations was observed in the whole group, there was a decrease in gamma peak frequency in some subjects. This evidence strongly indicates a further need to explore the impact of antidepressants on gamma-oscillation in larger samples. Interestingly, single administration of three drugs, including zolpidem, gaboxadol and tiagabine, targeting different aspects of the GABA system, tended to reduce parietal high frequency gamma rhythms, most notably with tiagabine (Nutt et al., 2015) . Recently, a significant decrease in peak gamma frequency was observed after single intravenous ketamine administration in healthy male volunteers (Shaw et al., 2015) .
Taken together, our MRS results raise additional questions as to whether SSRIs reliably modulate brain metabolites in the OCC area. However, our finding suggests there may be value in further exploring the possible effect of SSRIs and other antidepressants on gamma-oscillation in clinical samples, particularly in depression and anxiety, with the hypothesis that a decrease in peak gamma frequency might relate to treatment efficacy. Figure 1 . Effect of short-term treatment with escitalopram on the gamma peak frequency in healthy subjects.
